User login
Key clinical point: Accelerated partial breast irradiation (APBI) using multicatheter brachytherapy after breast-conserving surgery is as effective as and safer than whole breast irradiation (WBI) and can be an excellent alternative to WBI in patients with early breast cancer (BC).
Major finding: The 10-year local recurrence rate was similar in the WBI (1.58%) and APBI (3.51%) groups (P = .074), and the incidence of treatment-related late side-effects worse than grade 2 was significantly lower in the APBI vs WBI group (P = .021).
Study details: Findings are from the phase 3, GEC-ESTRO trial including 1328 women with early invasive BC who were randomly assigned to receive WBI or APBI.
Disclosures: This study was funded by German Cancer Aid, Germany. Some authors declared receiving grants, consulting fees, financial support, or payment from several sources.
Source: Strnad V, Polgár C, et al, on behalf of Groupe Européen de Curiethérapie and European Society for Radiotherapy and Oncology. Accelerated partial breast irradiation using sole interstitial multicatheter brachytherapy compared with whole-breast irradiation with boost for early breast cancer: 10-year results of a GEC-ESTRO randomised, phase 3, non-inferiority trial. Lancet Oncol. 2023 (Feb 1). Doi: 10.1016S1470-2045(23)00018-9
Key clinical point: Accelerated partial breast irradiation (APBI) using multicatheter brachytherapy after breast-conserving surgery is as effective as and safer than whole breast irradiation (WBI) and can be an excellent alternative to WBI in patients with early breast cancer (BC).
Major finding: The 10-year local recurrence rate was similar in the WBI (1.58%) and APBI (3.51%) groups (P = .074), and the incidence of treatment-related late side-effects worse than grade 2 was significantly lower in the APBI vs WBI group (P = .021).
Study details: Findings are from the phase 3, GEC-ESTRO trial including 1328 women with early invasive BC who were randomly assigned to receive WBI or APBI.
Disclosures: This study was funded by German Cancer Aid, Germany. Some authors declared receiving grants, consulting fees, financial support, or payment from several sources.
Source: Strnad V, Polgár C, et al, on behalf of Groupe Européen de Curiethérapie and European Society for Radiotherapy and Oncology. Accelerated partial breast irradiation using sole interstitial multicatheter brachytherapy compared with whole-breast irradiation with boost for early breast cancer: 10-year results of a GEC-ESTRO randomised, phase 3, non-inferiority trial. Lancet Oncol. 2023 (Feb 1). Doi: 10.1016S1470-2045(23)00018-9
Key clinical point: Accelerated partial breast irradiation (APBI) using multicatheter brachytherapy after breast-conserving surgery is as effective as and safer than whole breast irradiation (WBI) and can be an excellent alternative to WBI in patients with early breast cancer (BC).
Major finding: The 10-year local recurrence rate was similar in the WBI (1.58%) and APBI (3.51%) groups (P = .074), and the incidence of treatment-related late side-effects worse than grade 2 was significantly lower in the APBI vs WBI group (P = .021).
Study details: Findings are from the phase 3, GEC-ESTRO trial including 1328 women with early invasive BC who were randomly assigned to receive WBI or APBI.
Disclosures: This study was funded by German Cancer Aid, Germany. Some authors declared receiving grants, consulting fees, financial support, or payment from several sources.
Source: Strnad V, Polgár C, et al, on behalf of Groupe Européen de Curiethérapie and European Society for Radiotherapy and Oncology. Accelerated partial breast irradiation using sole interstitial multicatheter brachytherapy compared with whole-breast irradiation with boost for early breast cancer: 10-year results of a GEC-ESTRO randomised, phase 3, non-inferiority trial. Lancet Oncol. 2023 (Feb 1). Doi: 10.1016S1470-2045(23)00018-9